Elucidating Community-Acquired Pneumonia in Immunocompromised Individuals

In a prospective cohort study, 10% of patients hospitalized with CAP were immunocompromised and had longer hospital stays and higher mortality.

While immunocompromised hosts (ICH) clearly have elevated risk for pneumonia, data are scant regarding epidemiology and outcomes associated with community acquired pneumonia (CAP) in this population. Now, researchers have examined data from a prospective population-based cohort study of 7449 adult patients hospitalized for CAP in Louisville, Kentucky, from 2014–2016 (prior to the COVID-19 pandemic).

In all, 10% of the study population were either immunocompromised or severely immunocompromised. The most common immunocompromising conditions were advanced cancer (53%; predominantly lung cancer), cancer chemotherapy (23%), and use of corticosteroids (20%) or disease modifying antirheumatic drugs (10%). Compared with non-immunocompromised hosts,…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Elucidating Community-Acquired Pneumonia in Immunocompromised Individuals

Topics

Reviewing Author